Acute lymphoblastic leukemia (ALL) is a well-known malignant disorder affecting both children and adults. Althouhg the therapeutic limits have been maximized and optimized greatly, a better understanding of ALL is required for further improvements as prognostic value and cancer risk, to name a few. The genetic background has been revealed as critical to further improve the prognosis and diagnosis of ALL and other multiple malignant disorders. Hence this project proposes to study the individual genetic polymorphisms in Mdm4, a downstream gene in the P53 pathway in order to determine the susceptibility to this affection in the Caucasain population in Barcelona, Spain
Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To ana...
Acute myeloid leukemia patients with complex karyotype (CK-AML) account for approximately 10-15% of ...
Previous studies have shown that MDM2 SNP309 and p53 codon 72 have modifier effects on germline P53 ...
To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lym...
To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lym...
Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important cause of morb...
As a heterogeneous kind of malignances, Non-Hodgkin lymphoma (NHL) is the most common hematologic ca...
A number of single nucleotide polymorphisms have been associated with disease predisposition in chro...
A number of single nucleotide polymorphisms have been associated with disease predisposition in chro...
A number of single nucleotide polymorphisms have been associated with disease predisposition in chro...
Every year, acute lymphoblastic leukaemia (ALL) affects about 400 children aged <15 years in France,...
Adult acute lymphoblastic leukemia (ALL) is characterized by a high frequency of abnormal karyotypes...
Methotrexate and 6-mercaptopurine, important components of acute lymphoblastic leukemia treatment, a...
Acute myeloid leukemia patients with complex karyotype (CK-AML) account for approximately 10–15 % of...
<div><p>As a heterogeneous kind of malignances, Non-Hodgkin lymphoma (NHL) is the most common hemato...
Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To ana...
Acute myeloid leukemia patients with complex karyotype (CK-AML) account for approximately 10-15% of ...
Previous studies have shown that MDM2 SNP309 and p53 codon 72 have modifier effects on germline P53 ...
To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lym...
To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lym...
Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important cause of morb...
As a heterogeneous kind of malignances, Non-Hodgkin lymphoma (NHL) is the most common hematologic ca...
A number of single nucleotide polymorphisms have been associated with disease predisposition in chro...
A number of single nucleotide polymorphisms have been associated with disease predisposition in chro...
A number of single nucleotide polymorphisms have been associated with disease predisposition in chro...
Every year, acute lymphoblastic leukaemia (ALL) affects about 400 children aged <15 years in France,...
Adult acute lymphoblastic leukemia (ALL) is characterized by a high frequency of abnormal karyotypes...
Methotrexate and 6-mercaptopurine, important components of acute lymphoblastic leukemia treatment, a...
Acute myeloid leukemia patients with complex karyotype (CK-AML) account for approximately 10–15 % of...
<div><p>As a heterogeneous kind of malignances, Non-Hodgkin lymphoma (NHL) is the most common hemato...
Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To ana...
Acute myeloid leukemia patients with complex karyotype (CK-AML) account for approximately 10-15% of ...
Previous studies have shown that MDM2 SNP309 and p53 codon 72 have modifier effects on germline P53 ...